Bristol Offers Yervoy For Free In New Early Melanoma Indication
This article was originally published in The Pink Sheet Daily
New program gives free treatment with the checkpoint inhibitor for up to three years to patients taking 10 mg/kg dose as adjuvant therapy after surgery.
You may also be interested in...
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
The latest drug development news and highlights from our FDA Performance Tracker.
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.